亚洲EGFR突变非小细胞肺癌:EGFR抑制剂单药与联合治疗更新
本文综述亚洲EGFR突变非小细胞肺癌的流行病学与生物学基础,并讨论EGFR-TKI单药及联合化疗、抗血管生成、EGFR/MET靶向治疗的临床证据;获得性耐药不可避免,联合策略具有合理性。
要点
- EGFR突变肺癌在亚洲非小细胞肺癌中占比高,尤其见于不吸烟者、女性和腺癌组织学患者。
- EGFR-TKI代际更迭显著改善生存,但晚期患者获得性耐药仍不可避免。
- 耐药机制涉及遗传与非遗传机制,支持EGFR-TKI联合化疗、抗血管生成及EGFR/MET靶向治疗。
核心结论
- EGFR突变肺癌在亚洲非小细胞肺癌中占主要亚型,其高发机制涉及宿主遗传易感性、内源性突变过程和外源性暴露等多因素。
- EGFR-TKI单药治疗生存显著改善,但晚期患者获得性耐药仍不可避免,联合策略具有临床合理性。
研究设计与样本
- 本文为综述,汇总亚洲EGFR突变非小细胞肺癌的流行病学、生物学基础及EGFR-TKI单药与联合治疗的临床证据。
主要发现
- EGFR突变肺癌在亚洲不吸烟者、女性和腺癌组织学患者中富集,该临床病理特征已被认识超过二十年。
- 获得性耐药由遗传和非遗传机制驱动,包括继发性EGFR改变、旁路通路激活、TP53相关基因组不稳定、适应性突变和药物耐受持久状态。
- 炎症微环境线索可能促进已有致癌克隆扩增,突变特征提供相应基因组足迹。
临床怎么用
- 对亚洲非小细胞肺癌患者应关注EGFR突变高发临床特征,合理开展分子检测。
- 晚期EGFR突变患者接受EGFR-TKI治疗时需预期获得性耐药,并基于耐药机制考虑联合化疗、抗血管生成或EGFR/MET靶向治疗。
局限性
- 亚洲人群EGFR突变频率过高的机制仅部分明确。
- 联合治疗策略的临床证据仍在积累中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
EGFR-mutant lung cancer represents a major subtype of non-small cell lung cancer in Asia, with particularly high prevalence in never-smokers, women, and patients with adenocarcinoma histology. Although this clinicopathologic enrichment has been recognized for more than two decades, the mechanisms underlying the excess frequency of EGFR-mutant disease in Asian populations remain only partially understood. Accumulating evidence suggests a multifactorial basis involving host genetic susceptibility and diversity, endogenous mutational processes and exogenous exposures such as ambient particulate matter. In particular, recent genomic and experimental studies support a tumour-promotion framework in which inflammatory microenvironmental cues may facilitate the outgrowth of pre-existing oncogenic clones, while mutational signatures provide genomic footprints of these processes. In parallel, the treatment landscape for EGFR-mutant non-small cell lung cancer has evolved substantially with successive generations of EGFR tyrosine kinase inhibitors (EGFR-TKIs), leading to marked improvements in survival. However, acquired resistance remains inevitable in most patients with advanced disease and is driven by both genetic and non-genetic mechanisms, including secondary EGFR alterations, bypass pathway activation, TP53-associated genomic instability, adaptive mutagenesis, and drug-tolerant persister states. These insights have provided a strong rationale for combination strategies beyond EGFR-TKI monotherapy. In this review, we summarize current understanding of the epidemiology and biological basis of EGFR-mutant lung cancer in Asia and discuss the preclinical rationale and emerging clinical evidence supporting combination approaches with chemotherapy, anti-angiogenic agents, and EGFR/MET-directed therapies.
引用
- Sunaga N, Hasegawa Y, Sato M, et al. Targeting EGFR-Mutant Non-Small Cell Lung Cancer in Asia: An Update on Monotherapy and Combination Therapy With EGFR Inhibitors. Respirology. 2026. PMID: 42749289. doi:10.1002/resp.70315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。